Date: 2013-09-03
Type of information: Series B financing round
Company: Arsanis (USA - MA)
Investors: NeoMed Management (Switzerland) OrbiMed Advisors (USA -NY), Polaris Venture Partners (USA - MA) SV Life Sciences (USA - MA)
Amount: $20 million
Funding type: series B financing round
Planned used: The funds will be used to focus on the clinical development of Arsanis' lead program against Staphylococcus aureus, ASN-100 and to mature a pipeline of anti-infective antibodie sagainst other relevant pathogens.
ASN-100 is a monoclonal antibody cocktail designed to prevent and treat severe hospital associated Staphylococcus aureus infections, and is currently in manufacture for clinical trials. Arsanis’ pipeline also includes preclinical monoclonal antibody programs against the multi-drug resistant gram negative pathogens Escherichia coli and Klebsiella pneumoniae,
and a further program targeting Streptococcus pneumoniae. Arsanis’ approach combines extensive in-house infectious disease expertise with world-class antibody discovery and optimization capabilities through a partnership with Adimab LLC (Lebanon, NH, USA).
Others: * On September 3, 2013, Arsanis announced that it has raised $20 million in a Series B financing. The funding round was led by new investor NeoMed Management, with participation from existing investors; OrbiMed Advisors, Polaris Venture Partners ,and SV Life Sciences (Boston, MA). Dr. Claudio Nessi from NeoMed Management will join the Arsanis board of directors. This latest funding follows the recent announcement that Arsanis has been successful in raising significant non-dilutive grant funding to expand its infectious disease antibody pipeline. To date, over $7 million has been received, with the potential for an additional $20 million of funding over the next three years.
Therapeutic area: Infectious diseases
